Clinical Trial Update: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the safety and efficacy of combining favezelimab (MK-4280) with pembrolizumab (MK-3475) in patients with hematologic malig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Favezelimab (favezelimab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: COMPLETED